AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.385
+0.375 (+2.882%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.010
Open13.010
Bid13.100 x 300
Ask13.450 x 100
Day's Range12.942 - 13.470
52 Week Range9.830 - 27.490
Volume1,181,508
Avg. Volume1,177,680
Market Cap598.649M
Beta1.17
PE Ratio (TTM)N/A
EPS (TTM)-3.169
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.56
Trade prices are not sourced from all markets
  • An In-Depth Look at Achaogen’s Cash Flow
    Market Realist2 days ago

    An In-Depth Look at Achaogen’s Cash Flow

    Achaogen (AKAO) used $95.2 million in operating activities in fiscal 2017 compared to $46.9 million in fiscal 2016. Achaogen’s stock-based compensation expenses were $14.2 million, and its net change in operating assets and liabilities was $16.1 million in fiscal 2017. Achaogen raised $130.4 million from financing activities in fiscal 2017 compared with $135.4 million in fiscal 2016.

  • Achaogen’s Financial Performance
    Market Realist3 days ago

    Achaogen’s Financial Performance

    Achaogen (AKAO) generated contract revenue of $11.1 million in fiscal 2017 compared to $41.7 million in fiscal 2016. The revenue is derived from Achaogen’s non-profit and US government contracts.

  • A Look at Achaogen’s Research Pipeline
    Market Realist3 days ago

    A Look at Achaogen’s Research Pipeline

    The FDA accepted Achaogen’s (AKAO) NDA (New Drug Application) for plazomicin in January 2018 for treating cUTIs (complicated urinary tract infections), including acute pyelonephritis and bloodstream infections. The NDA was supported by data from two Phase 3 clinical trials, EPIC and CARE. The FDA granted priority review for the NDA and set a target date of June 25, 2018, under the Prescription Drug User Fee Act. Achaogen expects to launch plazomicin commercially in 2018 in the United States. It plans to submit a European Union marketing authorization application in 2018.

  • Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
    Market Realist3 days ago

    Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

    Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.

  • Analysts’ Ratings for Achaogen and Peers in April 2018
    Market Realist3 days ago

    Analysts’ Ratings for Achaogen and Peers in April 2018

    Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.

  • What Analysts Recommend for CymaBay Therapeutics
    Market Realist4 days ago

    What Analysts Recommend for CymaBay Therapeutics

    CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.

  • GlobeNewswire11 days ago

    Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    --Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae--. SOUTH SAN FRANCISCO, Calif., April 10, ...

  • Peninsula anti-aging drug company files for $85M IPO
    American City Business Journals15 days ago

    Peninsula anti-aging drug company files for $85M IPO

    This Brisbane company is one of the fastest-growing companies in the anti-aging space, focusing on cellular senescence.

  • Barrons.com17 days ago

    [$$] A Billionaire's Latest Biotech Bet

    Billionaire Bob Duggan never finished college, but according to his website, “much of his formal training was through communications and business programs offered by Scientology.” Duggan says on his site that he became an investor by “applying the lessons he learned from the published works of L. Ron Hubbard, founder of Scientology, and the University of California, Santa Barbara, to real life.” He took a course with UCSB’s Herbert C. Kay, whom he considers “a mentor.” Duggan has given back to those two sources of inspiration. Duggan didn’t respond to requests for comment made by phone and email. Duggan’s initial forays were marked with humility and success.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of AKAO earnings conference call or presentation 27-Feb-18 9:30pm GMT

    Q4 2017 Achaogen Inc Earnings Call

  • TheStreet.com26 days ago

    7 Well-Known Stocks That Are Set to Reverse Direction

    These equities are showing technical characteristics of bullish and bearish reversal patterns.

  • TheStreet.com27 days ago

    2 Small Biotechs That Continue to Look Good

    Several biotech names held up well or even had solid advances during last week's broad market selloff.

  • GlobeNewswirelast month

    Achaogen Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., March 22, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today ...

  • GlobeNewswirelast month

    Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin

    --Meeting planned for May 2, 2018--. SOUTH SAN FRANCISCO, Calif., March 21, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant ...

  • GlobeNewswirelast month

    Achaogen to Present at Needham & Company’s 17th Annual Healthcare Conference

    --Company presentation scheduled for March 27, 2018--. SOUTH SAN FRANCISCO, Calif., March 14, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing ...

  • ACCESSWIRElast month

    Wired News – Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and Biology

    Stock Monitor: Achaogen Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 08, 2018 / Active-Investors.com has just released a free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB ) ("Cellectar"). ...

  • GlobeNewswire2 months ago

    Achaogen to Present at the Cowen and Company 38th Annual Health Care Conference

    --Company presentation scheduled for March 13, 2018--. SOUTH SAN FRANCISCO, Calif., March 06, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing ...

  • When Can We Expect A Profit From Achaogen Inc (NASDAQ:AKAO)?
    Simply Wall St.2 months ago

    When Can We Expect A Profit From Achaogen Inc (NASDAQ:AKAO)?

    Achaogen Inc’s (NASDAQ:AKAO): Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. On 31 December 2017, theRead More...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, March 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswire2 months ago

    Achaogen Enters Into New $50 Million Secured Credit Facility with Silicon Valley Bank

    SOUTH SAN FRANCISCO, Calif. , March 1, 2018 /PRNewswire/ --  Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) ...

  • Associated Press2 months ago

    Achaogen reports 4Q loss

    The South San Francisco, California-based company said it had a loss of 98 cents per share. The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...

  • GlobeNewswire2 months ago

    Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

    --Plazomicin New Drug Application accepted by U.S. Food and Drug Administration; June 25, 2018 set as PDUFA action date--. --Orally-administered antibacterial candidate C-Scape achieved positive top-line ...

  • ACCESSWIRE2 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time. ...

  • GlobeNewswire2 months ago

    Achaogen Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today ...

  • GlobeNewswire2 months ago

    Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018

    SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant gram-negative infections, ...